Emmetrope Ophthalmics LLC, (aka “Emmecell”) is a privately held, clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of eye diseases via its exclusive Magnetic Cell Delivery (MCD) nanoparticle platform technology.